EP1891020A2 - Verfahren zur herstellung von azoxystrobin unter verwendung von dabco als katalysator, und neue zwischenprodukte, die in diesen verfahren zum einsatz kommen - Google Patents

Verfahren zur herstellung von azoxystrobin unter verwendung von dabco als katalysator, und neue zwischenprodukte, die in diesen verfahren zum einsatz kommen

Info

Publication number
EP1891020A2
EP1891020A2 EP06726760A EP06726760A EP1891020A2 EP 1891020 A2 EP1891020 A2 EP 1891020A2 EP 06726760 A EP06726760 A EP 06726760A EP 06726760 A EP06726760 A EP 06726760A EP 1891020 A2 EP1891020 A2 EP 1891020A2
Authority
EP
European Patent Office
Prior art keywords
methyl
compound
formula
phenyl
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06726760A
Other languages
English (en)
French (fr)
Other versions
EP1891020B1 (de
Inventor
Alan John Whitton
Ewan Campbell Boyd
Jack Vass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Syngenta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34640147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1891020(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syngenta Ltd filed Critical Syngenta Ltd
Priority to PL06726760T priority Critical patent/PL1891020T3/pl
Priority to PL10013918T priority patent/PL2308825T3/pl
Priority to EP10013918.7A priority patent/EP2308825B1/de
Priority to SI200631638T priority patent/SI1891020T1/sl
Publication of EP1891020A2 publication Critical patent/EP1891020A2/de
Application granted granted Critical
Publication of EP1891020B1 publication Critical patent/EP1891020B1/de
Priority to CY20131100716T priority patent/CY1114548T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/317Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C07C67/327Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by elimination of functional groups containing oxygen only in singly bound form
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a process for preparing the strobilurin fungicide methyl (E)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (azoxystrobin) and a novel precursor thereof.
  • azoxystrobin is prepared by reacting 2-cyanophenol with methyl (ZT)-2-[2-(6-chloro- pyrimidin-4-yloxy)phenyl]-3-methoxyacrylate.
  • a high-yielding method for producing asymmetrical 4,6-bis(aryloxy)pyrimidine derivatives is disclosed in WO 01/72719 in which a 6-chloro-4-aryloxypyrimidine is reacted with a phenol, optionally in the presence of a solvent and/or a base, with the addition of from 2 to 40 mol % of l,4-diazabicyclo[2.2.2]octane (DABCO).
  • DABCO l,4-diazabicyclo[2.2.2]octane
  • the present invention is based on the discovery that, when preparing azoxystrobin or a novel acetal precursor of azoxystrobin using DABCO as a catalyst, significantly smaller amounts of this relatively expensive catalyst may be used than are contemplated in WO 01/72719 without compromising the yield. Apart from reducing the cost of manufacture, this has the added environmental benefit of reducing the quantity of catalyst discharged in the aqueous process effluent.
  • W has the meaning given above, with 2-cyanophenol, or a salt thereof (suitably potassium 2-cyanophenoxide) in the presence of between 0.1 and 2 mol % of 1,4- diazabicyclo[2.2.2]octane, or (b) reacting the compound of formula (III):
  • the process of invention comprises reacting a compound of formula (II):
  • W has the meaning given above, with 2-cyanophenol, or a salt thereof (suitably potassium 2-cyanophenoxide) in the presence of between 0.1 and 2 mol % of 1,4- diazabicyclo[2.2.2]octane.
  • the compound of formula (I) where W is the methyl 2-(3,3-dimethoxy)propanoate group C(CO 2 CH 3 )CH(OCH 3 ) 2 [that is, the compound methyl 2- ⁇ 2-[6-(2-cyanophenoxy) pyrimidin-4-yloxy]phenyl ⁇ -3,3-dimethoxypropanoate (hereinafter referred to as 'azoxystrobin acetal')], is a novel compound and forms part of the present invention.
  • the invention includes isolated azoxystrobin acetal in substantially pure form [that is in an isolated form which comprises from 85 to 100 weight %, preferably from 90 to 100 weight %, of azoxystrobin acetal].
  • the product obtained may include a proportion of the compound of formula (I) where W is the methyl (E)-2-(3- methoxy)acrylate group. This may happen because it is possible that methanol is eliminated from the methyl 2-(3,3-dimethoxy)propanoate group under the conditions of the process.
  • the process is carried out using a compound of formula (II) or a compound of formula (IV) where W is a mixture of the methyl 2-(3,3-dimethoxy)propanoate group and the methyl (E)-2-(3-methoxy)acrylate group (and the invention includes such a process)
  • the product obtained will be a compound of formula (I) where W is a mixture of the methyl 2-(3,3-dimethoxy)propanoate group and the methyl (£) ⁇ 2-(3-methoxy)acrylate group; however, the product may have a higher proportion of the compound of formula (I) where W is the methyl (E)-2-(3-methoxy)acrylate group than expected from the proportion of (E)-2-(3- methoxy)acrylate group in the mixed starting material due to this potential elimination of methanol.
  • the process of the invention is carried out in a suitable inert solvent or diluent.
  • suitable inert solvent or diluent include, for example, aliphatic, alicyclic and aromatic hydrocarbons, such as petroleum ether, hexane, heptane, cyclohexane, methylcyclohexane, benzene, toluene, xylene and decalin; halogenated hydrocarbons, such as chlorobenzene, dichlorobenzene, dichloromethane, chloroform, carbon tetrachloride, dichloroethane and trichloroethane; heteroaromatic solvents such as pyridine or a substituted pyridine, for example, 2,6-dimethylpyridine; ethers, such as diethyl ether, dizsopropylether, methyl-tert-butyl ether, methyl-tert-amyl ether, dioxane,
  • Particularly suitable diluents are ketones [such as methyl wobutyl ketone and cyclohexanone], esters [such as isopropyl acetate], tertiary amines [such as [N,7V-dizsopropylethylamine (H ⁇ nig's base)] and amides [such as ⁇ N-dimethylformamide].
  • ketones such as methyl wobutyl ketone and cyclohexanone
  • esters such as isopropyl acetate
  • tertiary amines such as [N,7V-dizsopropylethylamine (H ⁇ nig's base)
  • amides such as ⁇ N-dimethylformamide.
  • methyl ⁇ obutyl ketone is used as diluent.
  • cyclohexanone is used as diluent
  • isopropyl acetate is used as diluent.
  • iV,iV-dirnethylformamide is used as diluent.
  • N,N-diwopropylethylamine H ⁇ nig's base
  • the diluent used in the present invention is N, N-dimethylformamide.
  • the process is carried out in aqueous two phase solvent system.
  • the 2-cyanophenol is present as a salt.
  • the salt is potassium 2-cyanophenoxide.
  • the water is removed throughout the reaction.
  • Suitable co-solvents for use in such an aqueous process are solvents which are at least partially water immiscible solvents such as cyclohexanone, methyl zs ⁇ butyl ketone and isopropyl acetate.
  • solvents which are at least partially water immiscible solvents such as cyclohexanone, methyl zs ⁇ butyl ketone and isopropyl acetate.
  • the salt of 2- cyanophenol is potassium 2-cyanophenoxide and the diluent is cyclohexanone, methyl isobv ⁇ yl ketone or isopropyl acetate. It is noted that when the 2-cyanophenol is added to the process as an aqueous solution of potassium 2-cyanophenoxide it is possible to reduce the quantity of acid acceptor (see below) used.
  • Suitable acid acceptors are all customary inorganic and organic bases. These include, for example, alkaline earth metal and alkali metal hydroxides, acetates, carbonates, bicarbonates and hydrides [such as sodium hydroxide, potassium hydroxide, sodium acetate, potassium acetate, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydride, sodium hydride and potassium hydride], guanidines, phosphazines (see, for example, Liebigs Ann.
  • acid acceptors are the alkaline earth metal and alkali metal carbonates, especially potassium carbonate and sodium carbonate and the tertiary amines l,5-diazabicyclo[4.3.0]non-5-ene and 1,8- diazabicyclo[5.4.0]undec-7-ene. More suitably, the acid acceptor is potassium carbonate.
  • the present invention is carried out in the presence of methyl isobutyl ketone, cyclohexanone, isopropyl acetate, 7V,N-diwopropylethylamine (Hiinig's base) or N,N-dimethylformarnide with potassium carbonate as the acid acceptor.
  • the process of the invention is carried out in the presence of between 0.1 and 2 mol% of 1 ,4-diazabicyclo[2.2.2]octane (DABCO), that is more than 0.1 but less than 2 mol% of DABCO.
  • DABCO 1 ,4-diazabicyclo[2.2.2]octane
  • it is carried out in the presence of between 0.2 and 2 mol% of DABCO.
  • Any amount of DABCO between 0.1 or 0.2 and 2, 0.1 or 0.2 and 1.9, 0.1 or 0.2 and 1.8, 0.1 or 0.2 and 1.7, 0.1 or 0.2 and 1.6 and 0.1 or 0.2 and 1.5 mol% is suitable, but the invention is of especial benefit in that the amount of DABCO used may be between 0.2 and 1.4 mol%. Normally it will be between 0.5 and 1.4 mol %, typically between 0.8 and 1.2 mol%, for example, about 1 mol%.
  • the process is carried out in the presence of about 1 mol% DABCO with methyl isobutyl ketone, cyclohexanone, isopropyl acetate, N,N-diwopropylethylamine (Hiinig's base), orN,N-dimethylforrnamide as diluent.
  • the diluent is N,iV-dimethylformamide.
  • the acid acceptor will be potassium carbonate.
  • the reaction temperature can be varied within a relatively wide range.
  • the temperature chosen will depend on the nature of the solvent or diluent, for example on its boiling point and/or its effectiveness for promoting the desired reaction, and on the speed at which the reaction is to be carried out. In any given solvent or diluent, the reaction will tend to progress more slowly at lower temperatures.
  • the reaction may be carried out at a temperature of from 0 to 12O 0 C, suitably at a temperature of from 40 to 100 0 C, and typically at a temperature of from 45 to 95 0 C, for example, from 60 to 85 0 C.
  • the process of the invention is carried out by mixing one of the components of the reaction, preferably in the presence of a solvent or diluent, with a base.
  • the other component is then added, if appropriate in the presence of a solvent or diluent, and the mixture is stirred, normally at an elevated temperature.
  • the DABCO catalyst may be added at any stage but is preferably added as the last component, as this tends to promote higher product yields.
  • the reaction mixture is worked up and the product is isolated using conventional techniques well known to a skilled chemist.
  • 2-Cyanophenol is a commercially available material.
  • the compound of formula (II), where W is the methyl (E)-2-(3-methoxy)acrylate group C(CO 2 CH 3 ) CHOCH 3
  • the compound of formula (II) where W is the methyl 2-(3,3-dimethoxy)propanoate group C(CO 2 CH 3 )CH(OCH 3 ) 2 may be prepared as described in WO 92/08703 from the reaction of 3-( ⁇ -methoxy)methylenebenzofuran-2(3H)-one (derived from benzofuran-2(3H)-one) with 4,6-dichloropyrimidine.
  • the compound of formula (II), where W is the methyl (E)-2-(3-methoxy)acrylate group may also be prepared by eliminating methanol from (that is, by the demethanolysis of) the compound of formula (II) where W is the methyl 2-(3,3-dimethoxy)propanoate group, as described in WO 92/08703 or WO 98/07707.
  • the compound of formula (II), where W is the methyl 2-(3,3-dimethoxy)propanoate group may be prepared as described in GB-A-2291874 by reacting a compound of formula (FV), where W is the methyl 2-(3,3-dimethoxy)propanoate group, with 4,6-dichloropyrimidine. It may be purified before use by known techniques or may be used in an unpurified state from a previous reaction, for example, in a 'one-pot' reaction.
  • the compound of formula (IV), where W is the methyl 2-(3,3-dimethoxy)propanoate group may be prepared as described in GB-A-2291874 from 3-( ⁇ -methoxy)methylene- benzofuran-2(3H)-one.
  • the compound of formula (IV), where W is the methyl (E)-2-(3- methoxy)acrylate group may be prepared by the demethano lysis of the compound of formula (IV) where W is the methyl 2-(3,3-dimethoxy)propanoate group. In this case the phenolic group needs to be protected by, for example, benzylation before demethanolysis and then de-protected afterwards.
  • the present invention includes a process for preparing a compound of formula (IV) where W is the methyl (E)-2-(3-methoxy)acrylate group, which comprises the steps of:
  • step (ii) eliminating methanol from the hydroxyl-protected compound formed in step (i); and (iii) removing the hydroxyl-protecting group formed in step (i) to form a compound of • formula (IV) where W is the methyl (E)-2-(3-methoxy)acrylate group.
  • step (i) of the process the compound of formula (IV) where W is the methyl 2-(3,3-dimethoxy)propanoate group is reacted with a standard protecting reagent, such as a benzyl halide or a substituted benzyl halide [such as a 2-nitrobenzyl halide], for example, benzyl bromide or 2-nitrobenzyl bromide, conveniently in a suitable solvent, such as N, iV-dimethylformamide, and a suitable base, such as potassium carbonate, to form a compound of formula (V):
  • a standard protecting reagent such as a benzyl halide or a substituted benzyl halide [such as a 2-nitrobenzyl halide], for example, benzyl bromide or 2-nitrobenzyl bromide
  • a suitable solvent such as N, iV-dimethylformamide
  • a suitable base such as potassium carbonate
  • Q is a protecting group, such as benzyl or 2-nitrobenzyl.
  • step (ii) of the process methanol is eliminated by any suitable physical or chemical means, for example, as described in WO 92/08703 or WO 98/07707. Conveniently, it is eliminated by treating a compound of formula (V) with methanesulphonic acid in the presence of acetic anhydride at a temperature in the range of, for instance, from 2O 0 C to
  • the protecting group may be removed by any standard technique for removing protecting groups, for example, by a reduction technique using hydrogen with a 10% palladium/carbon catalyst in ethyl acetate at ambient temperature.
  • the invention also includes novel intermediates of formula (V) where Q is a protecting group, and particularly the intermediate of formula (V) where Q is benzyl [that is, the compound methyl 2-(2-benzyloxy)phenyl-3,3-dimethoxypropanoate]. More particularly, the invention includes isolated methyl 2-(2-benzyloxy)phenyl-3,3-dimethoxypropanoate in substantially pure form [that is, in an isolated form which comprises from 85 to 100 weight %, preferably from 90 to 100 weight %, of methyl 2-(2-benzyloxy)phenyl-3,3-dimethoxy- propanoate].
  • This example describes a sequence of experiments designed to show the effect of decreasing the concentration of DABCO.
  • Toluene (160ml) and water (265mls) were added to the distillation residues and the two phase mixture heated to 70-80 0 C. The mixture was stirred for 40 minutes then settled and the lower aqueous phase separated.
  • the toluene solution (237.8g) contained methyl (E)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidm-4-yloxy]phenyl ⁇ -3- methoxyacrylate (41.3%w/w) 97.5% of theory.
  • Toluene (160ml) and water (265mls) were added to the distillation residues and the two phase mixture heated to 70-80 0 C. The mixture was stirred for 40 minutes then settled and the lower aqueous phase separated.
  • the toluene solution (227.9g) contained methyl (£)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrirnidin-4-yloxy]phenyl ⁇ -3- methoxyacrylate (43.6%w/w) 98.7% of theory.
  • Toluene (160ml) and water (265mls) at 6O 0 C were added to the distillation residues and the two phase mixture heated to 70-80 0 C. The mixture was stirred for 40 minutes then settled and the lower aqueous phase separated.
  • the toluene solution (243.Ig) contained methyl (E)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3- methoxyacrylate (38.6%w/w), 93.1% of theory.
  • Toluene 160ml was added to the distillation residues, maintaining the temperature between 70-80 0 C, followed by water (265mls) which had been heated to 6O 0 C. The mixture was stirred for 40 minutes at 8O 0 C and then settled and the lower aqueous phase separated.
  • the toluene solution 226.7g was contained methyl (E)-2 ⁇ 2-[6-(2- cyanophenoxy)pyrirnidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (41.5%w/w), 93.4% of theory.
  • Toluene 160ml was added to the distillation residues, maintaining the temperature between 60-70 0 C, followed by water (265mls) which had been heated to 6O 0 C, again maintaining the temperature between 60-70 0 C. The mixture was stirred for 40 minutes at 80 0 C and then settled and the lower aqueous phase separated.
  • the toluene solution 223.3g was contained methyl (E)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4- yloxy] ⁇ henyl ⁇ -3-methoxyacrylate (38.8%w/w) 86.6% of theory.
  • the yield of azoxystrobin formed in the process did not decrease greatly when the DABCO concentration was decreased below 2 mol%: even concentrations of DABCO of as low as 0.1mol% were sufficient to give a yield of 93.4% of theory.
  • the experiment containing no DABCO give a much lower yield, it also required 8 hours to reach this point compared to 5 hours for 0.1 mol% and .
  • 0.2 mol% DABCO and 60 minutes for 1.0 mol% and 2.0 mol% DABCO in this respect, it is also noted that the experiment containing 1.0 mol% DABCO surprisingly gave the a similar yield in the same time as the experiment containing 2.0 mol% DABCO).
  • Example 2c characterising data for methyl 2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3,3- dimethoxypropanoate are given.
  • Toluene (165.8g) was charged to the distillation residues and the temperature brought to 75 0 C before adding hot water (318.6g) and stirring for 30 minutes at 8O 0 C. The aqueous phase was removed and then the toluene layer was sampled and analysed. The solution yield of methyl (E)- 2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (azoxystrobin) was 90.0%. The toluene was distilled off under vacuum.
  • ArH are hydrogens bonded to phenyl rings; Hydrogens shown in bold in the assignment column are those which relate to that particular signal;
  • 'm' means multiplet signals; individual hydrogen signals are not fully resolved; 'd' means doublets; 's' means singlets;
  • Integrals indicates the number of hydrogens associated with the signal
  • Pyrimidine hydrogens are denoted as PyHx where x refers to the position of attachment of the hydrogen to the pyrimidine ring.
  • Methyl (E)-2- ⁇ 2-[6-chloropyrimidin-4-yloxy] ⁇ henyl ⁇ -3-methoxyacrylate (2Og at 97.1% strength; prepared as described in WO 92/08703) was added to MIBK (77ml) and water (1 ImI), followed by 2-cyanophenol (8.Og), DABCO (0.07g) and potassium carbonate (14.Ig). The reaction was heated to 8O 0 C and monitored for the end of the reaction (complete after 8 hours). The reaction mixture was washed with water at 8O 0 C. Analysis of the MIBK layer revealed a 95.7% yield of methyl (E)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4- yloxy]phenyl ⁇ -3-methoxyacrylate (azoxystrobin).
  • Methyl (E)-2- ⁇ 2-[6-chloropyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (98.4g at 97.7% strength; prepared as described in WO 92/08703) was added to MIBK (21Og) and water (38.3g) and heated to 45-5O 0 C.
  • 2-Cyanophenol (40.Ig), potassium carbonate (63.4g) and DABCO (0.5Ig) were added and the temperature was raised to 8O 0 C and held for 5.5 hours.
  • Water (316g) was added and agitation continued for 30 minutes before settling and separating the aqueous layer.
  • the dried solid contained methyl 2-[2-[6-(2-cyanophenoxy)- pyrimidin-4-yloxy]phenyl]-3,3-dimethoxy propanoate (90.8%w/w), 74.1% of theory ' and methyl (E)- 2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (2.41%w/w), 2.1% of theory.
  • the isopropyl acetate filtrates contained methyl 2-[2-[6-(2- cyanophenoxy)-pyrimidin-4-yloxy]phenyl]-3,3-dimethoxy propanoate (3.44%w/w), 8.75% of theory and methyl (E)- 2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3- methoxyacrylate (1.8%w/w), 4.95% of theory.
  • the resulting slurry was filtered, sucked dry on the filter and then dried in vacuo (45 0 C, 400mbar).
  • the dried solid contained methyl 2-[2-[6-(2-cyanophenoxy)-pyrimidin-4-yloxy]phenyl]-3,3- dimethoxy propanoate (81.19%w/w), 74.0% of theory and methyl (E)- 2- ⁇ 2-[6-(2- cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (18.55%w/w), 18.3% of theory.
  • the mixture was stirred at this temperature until the reaction was complete (3 hours).
  • the solvent was removed by vacuum distillation to 9O 0 C.
  • Toluene 130ml was added to the distillation residues, maintaining the temperature between 70-80 0 C, followed by water (21OmIs), maintaining the temperature as before.
  • the mixture was stirred for 10 minutes at 8O 0 C and then settled and the lower aqueous phase separated.
  • the toluene solution (180.2g) contained methyl (E)-2- ⁇ 2-[6-(2- cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (39.1%w/w) 87.4% of theory.
  • a slurry containing methyl (£)-2- ⁇ 2-[6-chloropyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (80.9g at 99%, 0.25mols), potassium carbonate (52.8g at 98%, 0.375mols) and 2- cyanophenol (33.6g at 97.5%, 0.275mols) in isopropyl acetate (13OmIs) was heated to approximately 6O 0 C.
  • a solution of DABCO (0.28g, 0.0025mols) in isopropyl acetate (1 OmIs) was added. The mixture was heated to 8O 0 C and held at this temperature for 360 minutes.
  • the isopropyl acetate was removed by vacuum distillation to a maximum temperature of 8O 0 C.
  • Toluene 160ml was added to the distillation residues, maintaining the temperature between 60-70 0 C, followed by water (265mls) which had been heated to 6O 0 C, again maintaining the temperature between 60-70 0 C.
  • the mixture was stirred for 40 minutes at 8O 0 C and then settled and the lower aqueous phase separated.
  • the toluene solution (229.8g) contained methyl (E)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3- methoxyacrylate (41.2%w/w) 94.2% of theory.
  • the washed organic phase (201.6g) contained methyl 2-[2-[6-(2-cyanophenoxy)-pyrimidin-4-yloxy]phenyl]-3,3-dimethoxypropanoate (22.5%w/w), 91.45% of theory and methyl (E)- 2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4- yloxy]phenyl ⁇ -3-methoxyacrylate (1.00%w/w), 4.4% of theory.
  • This example concerns experiments carried out to investigate whether the order of addition of the components makes a difference to the yield of azoxystrobin obtained. In particular, this example investigates whether yields are greater if the DABCO is added as the last component. a) Coupling of methyl (£ r )-2- ⁇ 2-[6-chloropyrimidin-4-yloxylphenyli-3-methoxyacrylate with 2-cyanophenol in MIBK with lmol% DABCO added after the 2-cyanophenol,, that is, last.
  • the mixture was stirred for 70 minutes then settled and the lower aqueous phase separated.
  • the MIBK solution (235.3g) contained methyl (E)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4- yloxyjphenyl ⁇ -3-methoxyacrylate (41.0%w/w) 95.8% of theory.
  • the M ⁇ BK solution (237.5g) contained methyl (E)-2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (39.0%w/w) 91.9% of theory.
  • the MIBK solution (237.Ig) contained methyl (E)-2- ⁇ 2-[6-(2- " cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (38.7%w/w) 89.1% of theory.
  • Example 3e gives an indication of the yield expected when higher concentrations of DABCO are used (2 mol%):
  • the mixture was heated to approximately 6O 0 C and then 2-cyanophenol (33.6g at 97.5%, 0.275mols) was charged. The mixture was heated to 8O 0 C and held at this temperature for 280 minutes. Water (30OmIs) was charged to the reaction, maintaining the temperature in the range 70-80 0 C. The mixture was stirred for 40 minutes then settled and the lower aqueous phase separated.
  • the MIBK solution (237.Og) contained methyl (E)-2- ⁇ 2-[6- (2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (40.2%w/w) 94.5% of theory.
  • Example 3e 2.0 mol% DABCO
  • Examples 3a and 3b 1.0 mol% DABCO
  • DMF solvent
  • This example concerns experiments carried out in an aqueous system.
  • the mixture was stirred at 75 0 C for 30 minutes, settled and the aqueous phase removed.
  • the organic phase (353.Ig) contained methyl 2-[2-[6-(2-cyanophenoxy)-pyrimidin-4-yloxy]phenyl]-3 ,3-dimethoxy propanoate (22.8%w/w) 72.6% of theory and methyl (E)- 2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4- yloxy]phenyl ⁇ -3-methoxyacrylate (4.47%w/w) 15.4% of theory.
  • the organic phase (233.Ig) contained methyl 2-[2- [6-(2-cyanophenoxy)-pyrimidin-4-yloxy]phenyl]-3,3-dimethoxy propanoate (25.09%w/w), 73% of theory and methyl (E)- 2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3- methoxyacrylate (4.96%w/w), 15.6% of theory.
  • the organic phase (373.2g) contained methyl 2-[2-[6-(2-cyanophenoxy)- pyrimidin-4-yloxy]phenyl]-3,3-dimethoxy propanoate (20.8%w/w) 68% of theory and methyl (E)- 2- ⁇ 2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl ⁇ -3-methoxyacrylate (3.52%w/w) 12.4% of theory.
  • Example 3 the surprising result seen in Example 3, with respect to the order of addition of DABCO, is also seen in the aqueous system - adding DABCO after the 2-cyanophenol (in the form of potassium 2-cyanophenoxide), that is, last, provides a higher yield than adding it before.
  • Step 1 The preparation of methyl 2-[(2-benzyloxy)phenyl]-(3,3-dimethoxy)propanoate.
  • Step 2 The preparation of methyl (E)-2-(2-benzyloxy)phenyl-3-methoxyacrylate.
  • a solution of methyl 2-[(2-benzyloxy)phenyl]-(3,3-dimethoxy) ⁇ ropanoate (5g; from Step 1) in acetic anhydride (7.Og) was heated to 4O 0 C and methanesulphonic acid (0.33g) added. After 90 minutes the mixture was allowed to cool to room temperature and toluene (25ml) was added. The resulting solution was washed with water (3x75ml) and then the toluene was evaporated in vacuo to give a liquid. After standing overnight crystals formed. These were isolated by filtration. A second crop was isolated from the filtrates after further concentration and trituration with ethanol. The combined yield of methyl (E)-2-(2-benzyloxy)phenyl-3-methoxyacrylate was 44%.
  • Step 3 The preparation of methyl (E)-2-(2-hydroxy)phenyl-3-methoxyacrylate.
  • Hydrogens shown in bold in the assignment column are those which relate to that particular signal
  • Integrals indicates the number of hydrogens associated with the signal.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
EP06726760.9A 2005-04-26 2006-04-13 Verfahren zur herstellung von azoxystrobin unter verwendung von dabco als katalysator, und neue zwischenprodukte, die in diesen verfahren zum einsatz kommen Active EP1891020B1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL06726760T PL1891020T3 (pl) 2005-04-26 2006-04-13 Sposoby wytwarzania azoksystrobiny z zastosowaniem DABCO jako katalizatora oraz nowe związki pośrednie stosowane w tych sposobach
PL10013918T PL2308825T3 (pl) 2005-04-26 2006-04-13 Sposób otrzymywania półproduktu azoksystrobiny
EP10013918.7A EP2308825B1 (de) 2005-04-26 2006-04-13 Verfahren zur Herstellung eines Zwischenprodukts für Azoxystrobin
SI200631638T SI1891020T1 (sl) 2005-04-26 2006-04-13 Postopki za pripravo azoksistrobina z uporabo katalizatorja DABCO in v postopkih uporabljene nove vmesne spojine
CY20131100716T CY1114548T1 (el) 2005-04-26 2013-08-21 Διεργασιες για την παρασκευη azoxystrobin με τη χρηση dabco ως καταλυτη και νεα ενδιαμεσα που χρησιμοποιουνται στις διεργασιες

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0508422.3A GB0508422D0 (en) 2005-04-26 2005-04-26 Chemical process
PCT/GB2006/001361 WO2006114572A2 (en) 2005-04-26 2006-04-13 Processes for the preparation of azoxystrobin using dabco as a catalyst and novel intermediates used in the processes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP10013918.7A Division EP2308825B1 (de) 2005-04-26 2006-04-13 Verfahren zur Herstellung eines Zwischenprodukts für Azoxystrobin
EP10013918.7 Division-Into 2010-10-25

Publications (2)

Publication Number Publication Date
EP1891020A2 true EP1891020A2 (de) 2008-02-27
EP1891020B1 EP1891020B1 (de) 2013-06-05

Family

ID=34640147

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06726760.9A Active EP1891020B1 (de) 2005-04-26 2006-04-13 Verfahren zur herstellung von azoxystrobin unter verwendung von dabco als katalysator, und neue zwischenprodukte, die in diesen verfahren zum einsatz kommen
EP10013918.7A Active EP2308825B1 (de) 2005-04-26 2006-04-13 Verfahren zur Herstellung eines Zwischenprodukts für Azoxystrobin

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10013918.7A Active EP2308825B1 (de) 2005-04-26 2006-04-13 Verfahren zur Herstellung eines Zwischenprodukts für Azoxystrobin

Country Status (30)

Country Link
US (1) US8124761B2 (de)
EP (2) EP1891020B1 (de)
JP (2) JP5107901B2 (de)
KR (1) KR101320492B1 (de)
CN (2) CN101163682B (de)
AR (1) AR055779A1 (de)
AU (2) AU2006238984B2 (de)
BR (1) BRPI0610381B1 (de)
CA (2) CA2808289C (de)
CL (1) CL2009001200A1 (de)
CY (1) CY1114548T1 (de)
DK (1) DK1891020T3 (de)
EA (1) EA013635B1 (de)
ES (2) ES2482144T3 (de)
GB (1) GB0508422D0 (de)
GE (2) GEP20115276B (de)
GT (1) GT200600171A (de)
HK (1) HK1119435A1 (de)
IL (2) IL186231A (de)
JO (1) JO2893B1 (de)
MY (2) MY145298A (de)
NZ (2) NZ561937A (de)
PL (2) PL2308825T3 (de)
PT (2) PT2308825E (de)
SI (1) SI1891020T1 (de)
TW (2) TWI385147B (de)
UA (2) UA107443C2 (de)
UY (2) UY29500A1 (de)
WO (1) WO2006114572A2 (de)
ZA (1) ZA200708582B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3660005A1 (de) 2018-11-28 2020-06-03 Sinon Corporation Verfahren zur herstellung von azoxystrobin

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619941D0 (en) * 2006-10-09 2006-11-15 Syngenta Ltd Chemical process
IL180134A0 (en) 2006-12-17 2007-07-04 David Ovadia Process for the preparation of substituted cyanophenoxy-pyrimidinyloxy -phenyl acrylate derivatives
IL181125A0 (en) * 2007-02-01 2007-07-04 Maktheshim Chemical Works Ltd Polymorphs of 3-(e)-2-{2-[6-(2-
CN102276538B (zh) * 2011-08-12 2015-01-28 河北威远生化农药有限公司 嘧菌酯及其关键中间体的制备方法
JP2015083541A (ja) * 2012-02-03 2015-04-30 アグロカネショウ株式会社 対称性4,6−ビス(アリールオキシ)ピリミジン化合物の製造方法
KR20130136671A (ko) 2012-06-05 2013-12-13 삼성디스플레이 주식회사 정전 용량 방식의 터치 패널 센서 및 이를 포함하는 터치 패널 표시 장치
CN102690237A (zh) * 2012-06-11 2012-09-26 江西中科合臣实业有限公司 一种合成高纯度嘧菌酯的方法
CN103214423B (zh) * 2013-03-20 2016-03-16 北京颖泰嘉和生物科技股份有限公司 一种丙烯酸酯类化合物的制备方法
CN103265496B (zh) * 2013-05-16 2015-02-25 北京颖泰嘉和生物科技有限公司 一种嘧菌酯的制备方法
TWI621614B (zh) 2013-05-28 2018-04-21 科麥農股份有限公司 4,6-雙(芳氧基)嘧啶衍生物的製備方法
WO2014203270A2 (en) * 2013-06-19 2014-12-24 Bhagiradha Chemicals & Industries Limited Process for the preparation of acrylate derivatives
CN103467387B (zh) * 2013-09-05 2016-03-16 北京颖泰嘉和生物科技股份有限公司 一种制备嘧菌酯及其中间体的方法
CN104672146A (zh) * 2013-11-26 2015-06-03 上海泰禾化工有限公司 一种新的高产率制备嘧菌酯的方法
WO2015102016A1 (en) * 2013-12-31 2015-07-09 Bhagiradha Chemicals & Industries Limited Process for the preparation of methyl 2-[2-(6-chloropyrimidin-4-yloxy) phenyl]-3,3- dimethoxypropionate
CN104292102A (zh) * 2014-07-29 2015-01-21 浙江颖欣化工有限公司 一种嘧菌酯中间体的制备方法
CN104230822B (zh) * 2014-09-16 2017-03-08 重庆紫光国际化工有限责任公司 嘧菌酯的合成方法
CN104230821B (zh) * 2014-09-16 2016-07-06 重庆紫光国际化工有限责任公司 嘧菌酯的合成方法
CN104230819B (zh) * 2014-09-16 2017-05-03 重庆紫光国际化工有限责任公司 嘧菌酯的合成方法
CN104230820B (zh) * 2014-09-16 2016-09-28 重庆紫光国际化工有限责任公司 嘧菌酯的合成方法
CN104974097B (zh) * 2015-05-29 2018-04-17 重庆紫光化工股份有限公司 一种嘧菌酯的合成方法
CN107235920A (zh) * 2017-07-29 2017-10-10 江苏绿叶农化有限公司 一种嘧菌酯的合成方法
CN109721548B (zh) * 2017-10-31 2020-11-13 南通泰禾化工股份有限公司 一种嘧菌酯的制备方法
CN110294716B (zh) 2018-03-23 2021-05-07 帕潘纳(北京)科技有限公司 一种嘧菌酯及其中间体的制备方法
BR112020020549A8 (pt) * 2018-04-23 2023-02-07 Msd Werthenstein Biopharma Gmbh Novo processo para síntese de um composto fenoxi diaminopirimidina
CN109529928B (zh) * 2018-11-16 2021-06-29 河北威远生物化工有限公司 一种催化剂体系及利用其制备嘧菌酯或其中间体的方法
CN113767093A (zh) * 2019-04-18 2021-12-07 Upl有限公司 用于制备嘧菌酯及其中间体的方法
KR102683529B1 (ko) * 2019-08-23 2024-07-09 주식회사 엘지화학 아족시스트로빈의 제조방법
CN114685376B (zh) * 2020-12-28 2024-06-07 北京颖泰嘉和生物科技股份有限公司 嘧菌酯中间体的制备方法
CN114685377B (zh) * 2020-12-31 2024-05-31 北京颖泰嘉和生物科技股份有限公司 嘧菌酯类化合物的制备方法
CN118084806A (zh) 2022-05-26 2024-05-28 安徽广信农化股份有限公司 一种制备嘧菌酯及其中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ213630A (en) * 1984-10-19 1990-02-26 Ici Plc Acrylic acid derivatives and fungicidal compositions
EP0387923B1 (de) * 1986-04-17 1994-02-16 Zeneca Limited Fungizide
GB9122430D0 (en) * 1990-11-16 1991-12-04 Ici Plc Chemical process
GB2255092A (en) * 1991-04-23 1992-10-28 Ici Plc 1,2,3-triazine fungicides
GB9415291D0 (en) 1994-07-28 1994-09-21 Zeneca Ltd Chemical process
GB9617351D0 (en) * 1996-08-19 1996-10-02 Zeneca Ltd Chemical process
GB9622345D0 (en) * 1996-10-28 1997-01-08 Zeneca Ltd Chemical process
JP2000191554A (ja) * 1998-12-29 2000-07-11 Nippon Soda Co Ltd 反応活性の高い官能基を有するアクリル酸誘導体の製造方法
DE10014607A1 (de) * 2000-03-24 2001-09-27 Bayer Ag Verfahren zur Herstellung von unsymmetrischen 4,6-Bis(aryloxy pyrimidin-Derivaten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006114572A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3660005A1 (de) 2018-11-28 2020-06-03 Sinon Corporation Verfahren zur herstellung von azoxystrobin

Also Published As

Publication number Publication date
AU2006238984B2 (en) 2011-04-21
AU2006238984A1 (en) 2006-11-02
TWI385147B (zh) 2013-02-11
GT200600171A (es) 2006-11-28
IL186231A0 (en) 2008-01-20
CL2009001200A1 (es) 2009-10-23
CN102126955B (zh) 2012-12-12
KR101320492B1 (ko) 2013-10-22
US20080214587A1 (en) 2008-09-04
CY1114548T1 (el) 2016-10-05
EA200702331A1 (ru) 2008-06-30
TW200643014A (en) 2006-12-16
CA2605323A1 (en) 2006-11-02
UA107443C2 (uk) 2015-01-12
UY29500A1 (es) 2006-11-30
MY144016A (en) 2011-07-29
DK1891020T3 (da) 2013-08-26
NZ586772A (en) 2011-07-29
UA90898C2 (ru) 2010-06-10
IL208667A0 (en) 2010-12-30
WO2006114572A3 (en) 2007-01-18
BRPI0610381B1 (pt) 2015-08-11
CA2605323C (en) 2013-10-01
GEP20115276B (en) 2011-08-25
AR055779A1 (es) 2007-09-05
AU2011201115A1 (en) 2011-04-07
JO2893B1 (en) 2015-09-15
BRPI0610381A2 (pt) 2012-10-23
EP1891020B1 (de) 2013-06-05
IL186231A (en) 2012-01-31
EP2308825A1 (de) 2011-04-13
PL1891020T3 (pl) 2013-11-29
ES2482144T3 (es) 2014-08-01
CN101163682B (zh) 2012-09-05
JP2008539214A (ja) 2008-11-13
CA2808289A1 (en) 2006-11-02
JP2012232998A (ja) 2012-11-29
NZ561937A (en) 2010-11-26
US8124761B2 (en) 2012-02-28
SI1891020T1 (sl) 2013-09-30
TW201217331A (en) 2012-05-01
PL2308825T3 (pl) 2014-10-31
UY37399A (es) 2018-02-28
JP5491589B2 (ja) 2014-05-14
EA013635B1 (ru) 2010-06-30
GEP20135956B (en) 2013-11-11
PT2308825E (pt) 2014-07-25
MY145298A (en) 2012-01-13
AU2011201115B2 (en) 2011-10-20
CN101163682A (zh) 2008-04-16
GB0508422D0 (en) 2005-06-01
CN102126955A (zh) 2011-07-20
EP2308825B1 (de) 2014-05-21
ES2425367T3 (es) 2013-10-15
CA2808289C (en) 2014-01-28
KR20080000612A (ko) 2008-01-02
WO2006114572A2 (en) 2006-11-02
PT1891020E (pt) 2013-09-02
ZA200708582B (en) 2008-11-26
HK1119435A1 (en) 2009-03-06
JP5107901B2 (ja) 2012-12-26
IL208667A (en) 2013-02-28

Similar Documents

Publication Publication Date Title
WO2006114572A2 (en) Processes for the preparation of azoxystrobin using dabco as a catalyst and novel intermediates used in the processes
EP2076498A1 (de) Herstellung von azoxystrobin
US20130060031A1 (en) Process for the preparation of highly pure ambrisentan
US6849762B2 (en) Process for preparing a trifluoroethoxy-substituted benzoic acid
US6593488B1 (en) 4-fluoro-3-oxocarboxylic esters and process for producing the same
EP3956317A1 (de) Verfahren zur herstellung von azoxystrobin und zwischenprodukten davon
EP3303312B1 (de) Verfahren zur herstellung von (e)-(5,6-dihydro-1,4,2-dioxazin-3-yl)(2-hydroxyphenyl)-methanon-o-methyloxim
JP2000327629A (ja) フェニル酢酸誘導体、ベンゾニトリル誘導体、およびその製造方法
JP2000327622A (ja) フェニル酢酸誘導体の製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071126

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17Q First examination report despatched

Effective date: 20081028

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 67/327 20060101ALI20130108BHEP

Ipc: C07C 59/64 20060101ALI20130108BHEP

Ipc: C07C 67/31 20060101ALI20130108BHEP

Ipc: C07C 69/734 20060101ALI20130108BHEP

Ipc: C07D 239/52 20060101AFI20130108BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 615619

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006036658

Country of ref document: DE

Effective date: 20130801

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20130827

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E008251

Country of ref document: EE

Effective date: 20130822

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2425367

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20131015

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 14590

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20130401839

Country of ref document: GR

Effective date: 20131015

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E018483

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140306

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006036658

Country of ref document: DE

Effective date: 20140306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130605

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140413

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E008251

Country of ref document: EE

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140413

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141031

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

Effective date: 20180315

Ref country code: FR

Ref legal event code: CD

Owner name: SYNGENTA JEALOTT'S HILL INTERNATIONAL RESEARCH, GB

Effective date: 20180315

REG Reference to a national code

Ref country code: FR

Ref legal event code: RM

Effective date: 20180420

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240326

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240318

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240319

Year of fee payment: 19

Ref country code: IE

Payment date: 20240326

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20240327

Year of fee payment: 19

Ref country code: CZ

Payment date: 20240320

Year of fee payment: 19

Ref country code: BG

Payment date: 20240321

Year of fee payment: 19

Ref country code: PT

Payment date: 20240326

Year of fee payment: 19

Ref country code: GB

Payment date: 20240314

Year of fee payment: 19

Ref country code: SK

Payment date: 20240315

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240318

Year of fee payment: 19

Ref country code: PL

Payment date: 20240319

Year of fee payment: 19

Ref country code: LV

Payment date: 20240318

Year of fee payment: 19

Ref country code: FR

Payment date: 20240315

Year of fee payment: 19

Ref country code: DK

Payment date: 20240327

Year of fee payment: 19

Ref country code: BE

Payment date: 20240319

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240315

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240501

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240510

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240326

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240408

Year of fee payment: 19

Ref country code: IT

Payment date: 20240411

Year of fee payment: 19

Ref country code: SI

Payment date: 20240319

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240408

Year of fee payment: 19

Ref country code: HU

Payment date: 20240327

Year of fee payment: 19